Search Results
Site Search
Linnea Baudhuin, Ph.D., and Kate Kotzer, M.S., CGC, describe how Mayo Clinic Laboratories' postmortem genetic tests can provide answers after a sudden unexplained cardiac death. Test results are important for managing family members' risk...
The importance of blood inventory and diversity in supply - Insights
Maintaining a diverse and sufficient blood supply is essential for hospital care, as transfusions support many critical treatments. Several known red blood cell antigens make donor-recipient matching complex, especially across diverse...
Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for...
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating...
Hereditary peripheral neuropathy - Insights
Learn how our test menu can assist in identifying genetic causes across the spectrum of hereditary peripheral neuropathies.
Lipid assay improves cardiovascular risk prediction: Jeff Meeusen, Ph.D. - Insights
Jeff Meeusen, Ph.D., explains how Mayo Clinic Laboratories' new MI-Heart Ceramides assay helps guide the management of patients with mildly to moderately high cholesterol. The test measures levels of lipids beyond cholesterol that boost...
Updated assay guides diagnosis of autoimmune liver disease: Anne Tebo, Ph.D. - Insights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.
Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing...
New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. - Insights
Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test...
Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D. - Insights
Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal...
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay...
Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D. - Insights
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely...
Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of...
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' enhanced MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted...
Breast and Gynecological Cancer - Insights
Learn how our gynecological cancer and breast cancer treatment tests are designed to provide a detailed picture of a patient’s cancer diagnosis.
Anti-hypertensive drug monitoring - Insights
Learn how Mayo Clinic Laboratories’ anti-hypertensive drug panel can assist physicians in understanding the reasons for resistant hypertension in patients.
Learn more about our comprehensive menu of COVID-19 molecular, serology, and related testing.
Hereditary neuromuscular disorders - Insights
Find out how our distinctive approach to evaluating for inherited neuromuscular disorders uses phenotypic information to streamline diagnosis.
Learn how our pediatric neuro-oncology testing includes both comprehensive MayoComplete next-generation sequencing and chromosomal microarray.
CNS Demyelinating Disease Testing - Mayo Clinic Laboratories
We offer the only FACS assay for CNS Demyelinating Disease. Our testing ensures the highest senstivity and specificity, providing the most accurate results for patients.
Patient information - Insights
Learn more about how Mayo Clinic Laboratories’ lupus testing can helping patients understand their disease activity and flare risk.
Browse our full menu of testing for motor and sensory neuropathies, spastic paraplegia, amyloidosis, and brachial plexus, among other conditions.
Mayo Clinic Laboratory and Pathology Research Roundup: Aug. 21 - Insights
This week’s Research Roundup highlights how intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Mayo Clinic Laboratory and Pathology Research Roundup: June 25 - Insights
This week’s Research Roundup highlights the association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer.
July 2023 - Cytopathology and Pulmonary Pathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Cytopathology & Pulmonary Pathology.
Mayo Clinic Laboratory and Pathology Research Roundup: December 12 - Insights
This week's research roundup feature: Most patients with solitary bone plasmacytomas (SBP) progress to multiple myeloma (MM) after definitive radiation therapy as their primary treatment. Whether the presence of high-risk (HR) cytogenetic...
Mayo Clinic Laboratory and Pathology Research Roundup: January 16 - Insights
This week's research roundup feature: Understanding the incidence, causes, and trends of sudden cardiac death (SCD) among young competitive athletes is critical to inform preventive policies.
CPT codes and LOINC update: April 2024 - Insights
This page includes updates posted to Mayo Clinic Labs during the month of April.
Tests aid diagnosis of primary biliary cholangitis: Anne Tebo, Ph.D. - Insights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune...
Paraneoplastic Vision Loss Evaluation [Test in Focus] - Insights
Andrew McKeon, M,B., B.Ch., M.D., provides an overview of Mayo Clinic Laboratories' new paraneoplastic vision loss evaluation — a test that can help direct a cancer diagnosis and guide treatment. He reviews why this test was developed, when...
Short recordings surrounding disease diagnosis through new methods in testing and treatment.
Addiction rehab monitoring assay - Insights
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most...
Inflammatory Bowel Disease: IBDP2 - Insights
In this test specific episode of the "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.
Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel is the most comprehensive test available for inherited Parkinson's disease. The new panel covers all mutations known to cause the...
Guided by an algorithmic approach that supports the right test for the right patient in the right geographic region, Mayo Clinic Laboratories offers a robust portfolio of vector-borne disease tests for the most prevalent mosquito- and...
Toxicology Transformed: From Opioids to Saliva - A Chemistry-Centric Journey - Insights
As drug trends and diagnostic technologies evolve, toxicology must adapt to meet the demands of healthcare, workplace safety, and public health—focusing on opioid detection, CBD use, patient-centered testing, and new methods like saliva...
Angela Pickart, M.S., CGC, and Emily Lauer, M.S., CGC, explain how Mayo Clinic Laboratories' multigene panel helps identify the cause of hereditary ataxia. Precise diagnosis of this complex movement disorder helps guide patient treatment...
NELL-1 [Test in Focus] - Insights
Sanjeev Sethi, M.D., Ph.D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic certainty and...
CPT codes and LOINC update: January 2024 - Insights
This page includes updates posted to Mayo Clinic Labs during the month of January.
Check out how Mayo Clinic Laboratories’ full menu of B-cell lymphoma testing, which includes next-generation sequencing and FISH testing, can inform diagnosis and prognosis for patients.
CPT codes and LOINC update: May 2023 - Insights
This page includes updates posted to Mayo Clinic Labs during the month of May.
Discontinuation of Herpes Simplex Virus (HSV) IgM Testing - Insights
In this month’s “Hot Topic,” Elitza Theel, Ph.D., will discuss the over utilization of IgM serologic testing for herpes simplex virus and the recommendation by multiple agencies, including the CDC and the Infectious Diseases Society of...
MCL @Work: Brian Dukek - Insights
As a senior principal developer for the brand-new Process Innovation Through Automation Laboratory, Brian Dukek helps labs throughout the Department of Laboratory Medicine and Pathology evaluate new automation tools and streamline...
A shared journey through breast cancer: Samantha Duke and Jane Hanson - Insights
When Samantha Duke discovered she had breast cancer, she didn’t have to look far for support. Her mother Jane walked a similar path 16 years earlier. Inspired both by her mom and the strong network of healthcare physicians and professionals...
Sarcoma Informative Cases - Insights
Case #1 Case #2 Case #3 Case #4 Case #5 Sarcomas are malignant tumors that arise in the bone and soft tissue. With numerous subtypes of sarcoma that can
What's New in Health Care Reform: Jan. 23 - Insights
Top highlights include: Physician burnout now essentially a public health crisis, Americans more likely to die from opioid overdose than in a car accident, study identifies biomarkers to stratify patients for prostate cancer treatment, the...
What's New in Health Care Reform: Jan. 30 - Insights
Top highlights include: Alcohol overtakes Hepatitis C as the top reason for liver transplants, new research call vitamin D benefits into question, NIH funds first artificial pancreas study in the United States for pregnant women, cervical...
Our pharmacogenomics (PGx) testing, which is used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression.
Staffing to Workload in Phlebotomy Areas: Direct Effort - Insights
Mike Baisch, Principal Systems Engineer at Mayo Clinic, discusses staffing to workload in phlebotomy areas with a focus on direct effort through time spent with a patient or patient sample.
Our staff, our stories: Ahmed and Alison Bashier - Insights
Looking back on their wedding, the Bashiers feel the event was a shining example of how greater empathy and understanding can be fostered between two very different cultures via a communal exchange of customs and traditions on an intimate...